Company intelligence / Profile preview

FoxWayne Enterprises Acquisition

New York, New York, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

FoxWayne Enterprises Acquisition Corp. was a SPAC that raised $50 million in its January 2021 IPO. The company initially announced a merger with Aerami Therapeutics in December 2021, which was expected to close in Q1 2022, but this deal was mutually terminated in early 2022 due to unfavorable market conditions[8][14]. The company's extended deadline was April 22, 2022, with the option to extend to July 22, 2022[8].

Industry: Investors

Partnerships

Former merger partner: Aerami Therapeutics (terminated 2022)

Beyond the preview

Go deeper on FoxWayne Enterprises Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FoxWayne Enterprises Acquisition.

Explore the full profile